Norgine's ex-U.S. PEDMARQSI launched, with successful initial uptake reported during clinical trial STS-J01 in Japan.
4 reports, 2 independent
Updated Fri 00:00
Still developing
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Norgine's ex-U.S. PEDMARQSI launched, with successful initial uptake reported during clinical trial STS-J01 in Japan.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Norgine expands PEDMARQSI commercialization into Australia and New Zealand.1 source
Norgine launched ex-U.S. PEDMARQSI, achieving successful initial uptake in Japan for clinical trial STS-J01.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireFennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update ~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in th
- GlobeNewswireFennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TS